Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 3/20 | 0.38 |
| ▸ | PNP | P00491 | 3/20 | 0.35 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17662614 | 0.84 | PNP (0.46) | PNP | |
| Hydrochloric Acid SCHEMBL19328559 | 0.82 | PNP (0.46) | PNP | |
| SCHEMBL17652035 | 0.81 | LMNA (0.35) | XDHPNPPOLB | |
| SCHEMBL19270444 | 0.80 | PNP (0.37) | XDHPNP | |
| SCHEMBL17652055 | 0.79 | PNP (0.45) | PNP | |
| Hydrochloric Acid SCHEMBL19253840 | 0.78 | PNP (0.44) | PNP | |
| SCHEMBL17652081 | 0.78 | LMNA (0.36) | XDHPOLB | |
| SCHEMBL19929245 | 0.75 | PNP (0.48) | PNP | |
| SCHEMBL19253834 | 0.69 | MPO (0.39) | — | |
| SCHEMBL19270442 | 0.69 | MPO (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170258797-A1 | TREATMENTS FOR AUTOIMMUNE DISEASE | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH (IE) | 2017-09-14 | — | — | US | disclosed |
| US-20170240553-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE DISEASES | THE PROVOST FELLOWS FOUNDATION SCHOLARS AND THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH (IE) | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240553-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE DISEASES | TYMS, DPYD, C5 | XDH 7/4885PNP 66/4885HPRT1 38/4885 |
| US-20170258797-A1 | TREATMENTS FOR AUTOIMMUNE DISEASE | QTRT1, QTRT2, HPRT1 | XDH 50/4885PNP 67/4885HPRT1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.